After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen's sales of its seven innovative products posted ... and improving balance sheet. That's why the Quant System anticipates 6.8% annual forward dividend growth. For more perspective, this ...

That was fueled by double-digit sales growth from 10 of its products ... Amgen’s Dividend Is Safe and the Balance Sheet Is Improving Amgen’s 3.4% dividend yield registers at twice the ...

Amgen's balance sheet has slightly improved ... but when excluding the impact of the acquisition, product sales still grew 8% with volume growth of 12%. Operating income increased slightly ...